Qudexy XR for the Prevention of Migraine in Children 6 to 11 Years Old

StatusRecruiting
PhasePhase 4
Started

Record status This record was last updated January 27, 2025 (before its estimated September 2026 completion). Its status may not reflect the trial's current state.

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Site details revised at 2 of 15 sitesv9
  2. Site details revised at 1 of 15 sitesv8
  3. Site details revised at 3 of 15 sitesv7
  4. Primary and study completion dates pushed to Sep 2026
    • Site details revised at 4 of 15 sites
    v6
  5. Study sites: 11 to 15v5
Show 3 earlier versionsHide 3 earlier versions
  1. Re-verified, no change to tracked fieldsv4
  2. Study sites: 2 to 11v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 2
    • Start date changed from estimate of Feb 2021 to Feb 19, 2021
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A Phase 4 study to evaluate Qudexy XR for the prevention of migraine in children 6 to 11 years of age.
Trial Details
NCT Number NCT04748601
Lead Sponsor Upsher-Smith Laboratories
Conditions
(from sponsor)		 Migraine Disorders
Related terms Migraine Disorders
Enrollment 132 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov